Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pharm Stat ; 10(2): 87-8, 2011.
Article in English | MEDLINE | ID: mdl-20143340

ABSTRACT

The following viewpoint from PSI and EFSPI regarding the current level of statistical resource in the European regulatory agencies was first presented as a position paper to a meeting of the EU Heads of Agencies in July 2009, and was endorsed by EFPIA.


Subject(s)
Data Interpretation, Statistical , Drug and Narcotic Control/statistics & numerical data , Government Agencies/organization & administration , European Union/statistics & numerical data , Humans
2.
J Acquir Immune Defic Syndr ; 51(1): 20-8, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19282778

ABSTRACT

BACKGROUND: Recently, the Data collection of Adverse events of Anti-HIV Drugs Group (D:A:D) described results from their international observational cohort of 33,347 HIV-1-infected individuals, suggesting unexpected increased risk of myocardial infarction (MI) associated with abacavir (ABC) therapy [relative rate 1.9, 95% confidence interval (CI): 1.47 to 2.45; P = 0.0001]. To contribute to the scientific question, we summarized GlaxoSmithKline HIV clinical trial data to determine if a similar signal emerged. METHODS: We compiled data from GlaxoSmithKline-sponsored clinical trials with > or = 24 weeks of combination antiretroviral therapy comprising 14,174 HIV-infected adults who received ABC (n = 9502; 7641 person-years) or not (n = 4672; 4267 person-years). FINDINGS: Baseline demographics and HIV disease characteristics, including lipids and glucose values, were similar. MI rates were comparable among subjects exposed [n = 16 (0.168%; CI: 0.096 to 0.273; 2.09 per 1000 person-years)] or not [n = 11 (0.235%; CI: 0.118 to 0.421; 2.57 per 1000 person-years)] to ABC-containing therapy. Results of 12 trials with randomization to ABC or not were consistent (2.15 per 1000 person-years vs. 4.10 per 1000 person-years). INTERPRETATIONS: In this pooled summary, we observed few MI events overall and no excess risk of MI with ABC therapy. It is unclear why results from this data set seem discrepant to the Data collection of Adverse events of Anti-HIV Drugs data set, particularly, as the non-ABC MI event rate is similar. Further data are needed to evaluate any association between ABC and increased risk of MI.


Subject(s)
Anti-HIV Agents/adverse effects , Dideoxynucleosides/adverse effects , HIV Infections/complications , HIV Infections/drug therapy , Myocardial Infarction/etiology , Adolescent , Adult , Adverse Drug Reaction Reporting Systems/statistics & numerical data , Aged , Clinical Trials as Topic/statistics & numerical data , Coronary Artery Disease/etiology , Data Interpretation, Statistical , Female , Humans , Male , Middle Aged , Risk Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...